Page last updated: 2024-11-12

1-methyl-3-octylimidazolium bromide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-methyl-3-octylimidazolium bromide: showed developmental toxicity on Daphnia magna [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10849985
SCHEMBL ID193258
MeSH IDM0528920

Synonyms (23)

Synonym
AKOS015833031
1-methyl-3-n-octylimidazolium bromide
61545-99-1
M1904
1-methyl-3-octylimidazolium bromide
AKOS015898333
SCHEMBL193258
1-methyl-3-octyl-1h-imidazol-3-ium bromide
1-octyl-3-methylimidazolium bromide
URVSXZLUUCVGQM-UHFFFAOYSA-M
1-n-octyl-3-methyl-imidazolium bromide
mfcd10566918
Q-102707
AS-65334
SY033841
1-methyl-3-octylimidazol-1-ium;bromide
D70824
1-methyl-3-n-octyl-imidazolium bromide
1-methyl-3-octylimidazoliumbromide
1-methyl-3-n-octylimidazolium bromide [omim]br
CS-W012326
1h-imidazolium, 3-methyl-1-octyl-, bromide (1:1)
c12h23brn2

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" These results indicate that [C(8)mim]Br has toxic effects on the early embryonic development of goldfish, and the risk to aquatic ecosystem by ILs leaking into the water body must be evaluated in the future."( Embryonic and developmental toxicity of the ionic liquid 1-methyl-3-octylimidazolium bromide on goldfish.
Huang, PP; Li, XY; Wang, CY; Wang, JJ; Wang, SH; Zhang, WH, 2010
)
0.61
"The toxic effects of 1-methyl-3-octylimidazolium bromide ([C8mim]Br) on wheat seedlings were evaluated."( Toxic effects of 1-methyl-3-octylimidazolium bromide on the wheat seedlings.
Ding, Y; Li, X; Liu, H; Liu, P; Sun, L; Wang, J, 2010
)
1.02
"This study investigated the cytotoxic, oxidative and genotoxic effects of two commonly used imidazolium ionic liquids (ILs), [bmim][BF4] (1-butyl-3-methylimidazolium) and [omim][BF4] (1-methyl-3-octylimidazolium tetrafluoroborate), on the marine mussel Mytilus galloprovincialis, as well as whether acetone could mediate their toxic profile."( Investigation of toxic effects of imidazolium ionic liquids, [bmim][BF4] and [omim][BF4], on marine mussel Mytilus galloprovincialis with or without the presence of conventional solvents, such as acetone.
Belavgeni, A; Dailianis, S; Tsarpali, V, 2015
)
0.42

Dosage Studied

ExcerptRelevanceReference
" Finally, we also found that the embryonic and developmental toxicity of [C(8)mim]Br on fish embryos was dose-response and developmental stage-specific."( Embryonic and developmental toxicity of the ionic liquid 1-methyl-3-octylimidazolium bromide on goldfish.
Huang, PP; Li, XY; Wang, CY; Wang, JJ; Wang, SH; Zhang, WH, 2010
)
0.61
" On the 7thd, the activity of glutathione-S-transferase in the 20 and 40mgkg(-1) dosage groups was inhibited while increased in the 80 and 160mgkg(-1) groups compared with the control groups."( Effects of 1-methyl-3-octylimidazolium bromide on the anti-oxidant system of earthworm.
Li, XY; Luo, YR; Wang, J; Wang, JJ; Yun, MX, 2010
)
0.75
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (18.75)29.6817
2010's12 (75.00)24.3611
2020's1 (6.25)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.69 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.52 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]